(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
The Best Business visionaries Under 30 - 2Aurora chaser catches a fox basking in the glow of Finland's legendary 'fox fires' (photos)
- 3My Excursion to Monetary Autonomy: Awesome ways to save cash
- 4Dental Embed Innovation: An Achievement in Helpful Dentistry
- 5Iranian-linked drone attack kills Kurdish couple in northern Iraq
- NASA’s Artemis II mission will take an astronaut crew around the Moon – a space policy expert describes the long road to launch
- Farmers call for French blockades over cow disease cull
- What an expert on the gut microbiome eats in a day
- At least 18 Palestinians killed in latest clashes in Gaza
- Germany unveils rescue plan for struggling chemical sector
- NASA's Artemis 2 moon launch may be visible from Florida and southern Georgia today. Here's when to look
- South African radio presenter among five charged over Russia recruitment plot
- Embracing Practical Living and Ecological Protection
- Journalists killed by Israeli strike in southern Lebanon
